

**IN THE SPECIFICATION.**

Please amend the paragraph starting on line 4 of page 1 as follows:

This is a continuation-in-part application of U.S. application serial number 09/289,346, filed April 9, 1999, pending now U.S. Patent No. 6,800,793, which claims priority to U.S. provisional application serial number 60/125,004, filed March 18, 1999, the entire contents of each of which are incorporated by reference herein.

Please amend the paragraph starting on line 31 of page 7 as follows:

**Figure 3** shows mutations generated in the oligomerization domain of AL1, and their characteristics. The wild-type amino acid sequence presented in Figure 3 corresponds to amino acids 115-180 of SEQ ID NO: 1.

Please amend the paragraph starting on line 9 of page 11 as follows:

FIG. 11B shows the helix 4 motifs of TGMV AL1 (amino acids 144-156; SEQ ID NO:100), TYLCV-DR C1 (amino acids 142-154; SEQ ID NO:101) and CbLCV AL1 (amino acids 141-153; SEQ ID NO:102). The conserved leucine residue in the helix center that was mutated to an alanine in CbL145 is marked with a dot. A consensus for begomovirus AL1/C1 proteins is shown at the bottom (SEQ ID NO:113).